Linzess is manufactured by Ironwood Pharmaceuticals and AbbVie [1].
What is Linzess used to treat?
Linzess is prescribed to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults [1].
How does Linzess work?
Linzess is a guanylate cyclase-C (GC-C) agonist. It works by increasing fluid secretion in the intestines, which helps to soften stool and promote bowel movements. It also helps to reduce abdominal pain associated with IBS-C [1].
When does Linzess's patent expire?
Information regarding the specific patent expiry dates for Linzess is available through drug patent tracking resources. For detailed patent information, DrugPatentWatch.com is a useful source [2].
Are there other medications like Linzess?
Other medications approved for IBS-C and CIC include linaclotide (which is Linzess), lubiprostone, and plecanatide. Each works through different mechanisms to relieve constipation symptoms [1].
What are the common side effects of Linzess?
The most common side effect reported with Linzess is diarrhea [1]. Other potential side effects include nausea, abdominal pain, and bloating. Patients experiencing severe diarrhea or other concerning symptoms should consult their healthcare provider [1].